Table 2.
Difference of the response to nivolumab according to the clinical parameters and CT morphological characteristics
| Parameters | Response to nivolumab, N | P‐value | |
|---|---|---|---|
| Age | ≥75 (n = 11) | 2 | 0.85 |
| <75 (n = 58) | 12 | ||
| Gender | Male (n = 52) | 14 | < 0.05 |
| Female (n = 17) | 0 | ||
| Smoking | Heavy smoker (n = 49) | 14 | < 0.05 |
| Light or never smoker (n = 20) | 0 | ||
| ECOG performance status | 0,1 (n = 64) | 13 | 0.987 |
| 2 (n = 5) | 1 | ||
| EGFR mutation | Positive (n = 8) | 1 | 0.547 |
| Negative (n = 60) | 13 | ||
| Histology | Squamous cell carcinoma (n = 16) | 4 | 0.286 |
| Others (n = 53) | 10 | ||
| Interstitial septal thickening | Positive (n = 16) | 1 | 0.093 |
| Negative (n = 50) | 13 | ||
| Peritumoral ground‐glass opacity | Positive (n = 37) | 5 | 0.099 |
| Negative (n = 30) | 9 | ||
| Spiculated margin | Positive (n = 13) | 1 | 0.21 |
| Negative (n = 56) | 13 | ||
| Air bronchogram | Positive (n = 6) | 1 | 0.817 |
| Negative (n = 63) | 13 | ||
| Cavity or necrosis | Positive (n = 14) | 3 | 0.906 |
| Negative (n = 55) | 11 | ||
| Adjacent organ invasion | Positive (n = 8) | 1 | 0.56 |
| Negative (n = 61) | 13 | ||
| Bulky lymph node (≥2.5 cm) | Positive (n = 10) | 2 | 0.98 |
| Negative (n = 59) | 12 | ||
| Accumulation of small lymph nodes | Positive (n = 3) | 1 | 0.566 |
| Negative (n = 66) | 13 |
Objective response rate could be evaluated in 69 of 78 subjects.
Heavy smoker, Brinkman index ≥400; Light or never smoker, Brinkman index <400.